Development of a Microsimulation Model for Cognitive Impairment and Dementia in Type 2 Diabetes Patients

Cognitive impairment and dementia (CID) are increasingly recognized as important complications of type 2 diabetes (T2D) that significantly impact affected individuals (including their diabetes management), their families, and healthcare systems. However, few recommendations are available to guide clinicians about how to prevent or treat CID in people with T2D. It is critical to understand the role of risk factors (e.g., comorbidities and frailty) for T2D-related dementia, and to identify and test traditional and new classes of drugs (e.g., sodium-glucose co-transporters) that reduce T2D-related dementia risk in clinical settings. The objectives of this pilot study are to develop and internally validate a preliminary microsimulation model for CID in patients with T2D. This will provide a framework for develop a full model to aid clinical trial design, project the long-term efficacy and cost-effectiveness of interventions, and inform health policy and resource allocation for dementia in the T2D population.